Exploring the Role of Oral JAK Inhibitors in Atopic Dermatitis - Episode 2

JAK1 Selective Inhibition and the Impact of Selectivity on Efficacy and Safety

Published on: March 21, 2025

Linda Stein Gold, MD, Lisa Swanson, MD, PhD, James Song, MD, Christopher G. Bunick, MD, PhD

Experts discuss the significance of using selective JAK1 inhibitors for atopic dermatitis (AD), noting their targeted action compared with nonselective JAK inhibitors, and how JAK1 selectivity enhances both the efficacy and safety of these agents in treating AD.

EP. 1: The Role of the JAK/STAT Signaling Pathway in Atopic Dermatitis

Now Viewing

EP. 2: JAK1 Selective Inhibition and the Impact of Selectivity on Efficacy and Safety

Video content above is prompted by the following:

The 2 approved oral JAK inhibitors for AD are selective for JAK1. What is the significance of using a selective JAK inhibitor in AD?
How do these agents differ from nonselective JAK inhibitors used in other disease states?
How does this JAK1 selectivity impact the efficacy and safety of these agents in AD?